Asensus Surgical Inc Stock Price, News & Analysis

Asensus Surgical (NYSE American: ASXC) announced that Paul LaViolette, Board Chair since 2013, will step down in late October due to professional commitments. David Milne, an existing board member, will succeed him. LaViolette praised the company’s evolution, emphasizing the potential of Performance-Guided Surgery and the Senhance Surgical System. Milne, experienced in medical technology, expressed honored to lead Asensus during its critical market development phase.

Asensus aims to transform surgery through digital innovation and enhanced surgeon control.

Asensus Surgical, Inc. (NYSE American: ASXC) has announced a partnership with Sapporo Medical University Hospital to utilize the Senhance® Surgical System, marking a significant expansion in Japan's surgical robotics landscape. This agreement enhances the hospital's capabilities, integrating advanced surgical technologies aimed at delivering superior patient outcomes. The Senhance platform utilizes augmented intelligence and offers unique features such as 3 mm instruments and machine vision-driven camera control.

Asensus Surgical, Inc. (ASXC) has announced that Loginov Moscow Clinical Scientific Center is the first Russian facility to implement the Senhance Surgical System. This robotic surgery program aims to enhance minimally invasive surgical options for patients. The Senhance platform integrates augmented intelligence, offering features such as haptic feedback and eye-tracking control. Loginov Moscow, a prominent institution with 48 medical departments and over 13,000 annual operations, intends to improve surgical outcomes through this advanced technology.

Asensus Surgical, Inc. (ASXC) announced that Anthony Fernando, CEO, and Shameze Rampertab, CFO, will present at three virtual investor conferences. The events include:

• H.C. Wainwright 23rd Annual Global Investment Conference: Recorded presentation available from September 13, 2021.
• Baird 2021 Global Healthcare Conference: Live presentation on September 14, 2021, at 2:35 PM ET.
• 2021 Cantor Virtual Global Healthcare Conference: Live presentation on September 28, 2021, at 1:20 PM ET.

Asensus Surgical has received FDA 510(k) clearance for enhanced machine vision capabilities on its Intelligent Surgical Unit™ (ISU™), expanding its digital surgery features. This upgrade includes 3D measurement, digital tagging, image enhancement, and improved camera control, all crucial for soft-tissue abdominal surgery. The ISU works alongside the Senhance® Surgical System, enhancing surgeon efficiency and precision. This is a significant step in Performance-Guided Surgery™, aiming to achieve superior surgical outcomes.

Asensus Surgical, Inc. (ASXC) reported its second-quarter 2021 results, highlighting significant growth in surgical procedures and revenue. The company performed over 1,000 procedures in the first half of 2021, a 175% increase year-over-year. Revenue rose to $1.1 million, up from $0.7 million a year ago, attributed to system sales, instruments, and services. The firm received FDA clearance for 5 mm articulating instruments, enhancing its Senhance Surgical System. Although net loss narrowed to $13.2 million, expenses increased to $14.8 million. Asensus aims to install 10-12 new systems in 2021.

Asensus Surgical (NYSE American: ASXC) has received FDA 510(k) clearance for 5 mm articulating instruments, enhancing its Senhance Surgical System. This addition allows for improved access during surgeries, offering two additional degrees of freedom. Previously granted a CE Mark in the EU, these instruments aim to expand clinical utility and surgical performance. The Senhance system stands out through its use of augmented intelligence, machine learning, and haptic feedback, setting a new standard in Performance-Guided Surgery.

Asensus Surgical, Inc. (NYSE American: ASXC) has expanded its Board of Directors by appointing Elizabeth Kwo, MD, and Kevin Hobert, effective immediately. Dr. Kwo brings expertise in healthcare technology and predictive analytics, while Hobert has a rich background in medical technology leadership. Both are expected to enhance Asensus’s efforts in advancing the Senhance Surgical System, aimed at revolutionizing digital surgery. Chairman Paul LaViolette emphasized their skills align with the company's vision for Performance-Guided Surgery.

Asensus Surgical, Inc. (ASXC) will release its second quarter financial and operating results on August 5, 2021, after market close. A conference call to discuss these results will begin at 4:30 p.m. ET, available via telephone and webcast. Asensus is focused on Performance-Guided Surgery, utilizing its Senhance® Surgical System and Intelligent Surgical Unit™ to enhance surgical outcomes and reduce variability. The system features advanced technologies such as machine vision and deep learning, aiming to transform surgery and healthcare value.